Cambridge-based Zetta Genomics has raised £1.9 million in a Seed II funding round, to further scale its genomic data management platform XetaBase, ahead of a Series A raise next year.
The round was led by Nina Capital and includes APEX Ventures and Cambridge Enterprise, the innovation arm of the University of Cambridge.
“Today’s seed funding exceeded our initial ask, showing the excitement building around Zetta Genomics’ game changing XetaBase data analytics platform. We now have the strategic headroom to configure for growth – to scale our technologies, enhance customer focus, and create a cycle of ongoing product innovation. This investment sees us one step closer to realising predictive, precision genomics – transforming research, healthcare and the lives of millions,” says Zetta Genomics CEO, Mark Bailey.
The company’s XetaBase genomic data management platform simplifies tertiary genomic data analysis – aggregating, indexing and enriching secondary data at scale and speed – to accelerate discovery, diagnosis and the delivery of genomic medicine.
“Zetta Genomics is a company in the right place at the right time with the right technology. Genomic-enabled predictive and precision medicine promises uniquely targeted research, therapeutics and care. Preventing avoidable conditions and treating disease efficiently and effectively, we will see radical improvements not just in health, but health economics. It is a future that depends on transformational genomic data management and analytics – and Zetta Genomics is uniquely positioned to deliver,” says Marc Subirats, Partner at Nina Capital.
Would you like to write the first comment?Login to post comments